Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis (OPAL BALANCE)

This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication.
January 23, 2014
Rheumatology - Psoriatic Arthritis
Philip J. Mease, MD
Allison Everett